The product license for Fostair® (beclometasone and formoterol) pressurised metered dose inhaler (pMDI) has been updated with a new indication to allow use as maintenance and reliever therapy.
The Summary of Product Characteristics advises that patients can take one inhalation of the inhaler regularly twice daily for maintenance and then take up to six additional inhalations as needed in response to symptoms.
Symbicort® (budesonide and formoterol) dry power inhalers (DPI) are already licensed in this way. The license extension for Fostair® now gives clinicians and patients a choice of delivery device (pMDI or DPI).
Action: Clinicians should be aware of the license extension. Patients who prefer pMDI devices may find this product more acceptable.
Thanks to Kevin Ashworth for highlighting this information
|« Drug Safety Update - February 2013||Hypnotics raise hip fracture risk »|